December 19, 2011 – The role of cardiovascular ultrasound in the catheterization laboratory has never been appreciated more than it is today. Transcatheter aortic valve implantation (TAVI) allows a multidisciplinary team of interventionalists and echocardiographers to replace a patient's diseased aortic valve without traditional open-heart surgery, enabling a new and potentially life-saving method of treatment for inoperable patients with severe symptomatic aortic stenosis.

“Echocardiography plays an essential role in transcatheter aortic valve replacement. It is required in the pre-procedural evaluation of patients for determining the severity of aortic valve stenosis and characterizing the aortic valve complex. It plays a critical role intra-procedurally throughout every stage of the procedure. Echocardiography is indispensable in the immediate post-implantation stage, when a timely evaluation of complications may prevent adverse outcomes. Finally, follow-up of patients with transcatheter valves requires continued echocardiographic monitoring,” said Rebecca Tung Hahn, M.D., FASE, director of interventional and valvular echocardiography at New York’s Columbia University.

Medical professionals worldwide have new recommendations for the use of echocardiography in identifying patients suitable for these interventions, providing intra-procedural monitoring, and in post-procedure follow-up. The EAE/ASE Recommendations for the Use of Echocardiography in New Transcatheter Interventions for Valvular Heart Disease, a collaborative effort between the American Society of Echocardiography (ASE) and the European Association of Echocardiography (EAE), were published in the September issue of the Journal of the American Society of Echocardiography (JASE).

The U.S. Food and Drug Administration (FDA)’s November approval of the transfemoral delivery of the Sapien transcatheter aortic heart valve was the first U.S. commercial approval of a transcatheter device.

“The FDA approval not only marks a new era for the treatment of aortic stenosis, but also a new era of collaboration and teamwork between echocardiographers and interventionalists,” said Douglas C. Shook, M.D., program director of the Cardiothoracic Anesthesia Fellowship at Brigham and Women’s Hospital at Harvard Medical School. “The echocardiographer is a co-proceduralist during these percutaneous interventions, guiding and assessing the progress and outcome in a real-time, continuous and stepwise manner. It is critical that, during placement of the transcatheter aortic valve, the interventionalist and echocardiographer maintain constant communication regarding anatomic structure and function, as well as progress of the procedure.”

Many, if not all, complications require rapid assessment of the device as well as other cardiac structures, and the echocardiographer’s ability to diagnose rapidly is essential to guiding swift corrective action. “This makes new demands of the echocardiographer, whether he/she is a cardiac anesthesiologist, cardiologist, or sonographer,” Shook said.

“The echocardiographer anticipates as well as responds to the imaging needs of the interventionalist, and so must have a complete understanding of every aspect of the interventional procedure itself,” said Hahn.

Because echocardiographers play such an integral role in this procedure, a session featuring live transmission of a transcatheter aortic valve implantation will take place in conjunction with ASE's 23rd Annual Scientific Sessions in National Harbor, Md. The transmission from the Washington Hospital Medical Center in Washington, D.C., on July 3, 2012, will feature interventional cardiologists and echo faculty.

As the largest global organization for cardiovascular ultrasound imaging, the American Society of Echocardiography (ASE) is the leader and advocate, setting practice standards and guidelines. Comprised of over 15,000 physicians, sonographers, nurses and scientists, ASE is a strong voice providing guidance, expertise and education to its members with a commitment to improving the practice of ultrasound and imaging of the heart and cardiovascular system for better patient outcomes.

Full text of ASE’s guidelines is available at www.asecho.org/guidelines.

For more information about ASE: www.asecho.org


Related Content

News | FDA

July 8, 2025 — Mendaera, Inc., a healthcare technology company focused on developing robotics that can be deployed ...

Time July 08, 2025
arrow
News | Point-of-Care Ultrasound (POCUS)

June 17, 2025 — Royal Philips has announced the global launch of the Flash Ultrasound System 5100 POC — a new point-of ...

Time June 19, 2025
arrow
News | Lung Imaging

June 18, 2025 — Exo recently announced that now included on its Exo Iris is the first ever FDA 510(k) cleared AI for ...

Time June 18, 2025
arrow
News | Artificial Intelligence

April 16, 2025 — An artificial intelligence (AI) program trained to review images from a common medical test can detect ...

Time April 16, 2025
arrow
News | Ultrasound Women's Health

April 11, 2025 — Contrast-enhanced ultrasound (CEUS) is a safe and accurate diagnostic imaging option for pregnant women ...

Time April 11, 2025
arrow
News | Focused Ultrasound Therapy

March 31, 2025 — Neuropathic pain affects up to 10 percent of the global population and can be challenging to manage ...

Time April 02, 2025
arrow
News | Breast Imaging

March 20, 2025 — GE HealthCare has launched Invenia Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound ...

Time March 21, 2025
arrow
News | X-Ray

March 18, 2025 — GE HealthCare recently announced a collaboration with NVIDIA expanding the existing relationship ...

Time March 19, 2025
arrow
News | Breast Imaging

Feb. 26, 2025 — iCAD, Inc. a provider of clinically proven AI-powered cancer detection solutions, and Koios Medical, a ...

Time March 03, 2025
arrow
News | Focused Ultrasound Therapy

Jan. 8, 2025 - EDAP TMS SA, a supplier of robotic energy-based therapies, has announced that the first patient has been ...

Time January 08, 2025
arrow
Subscribe Now